The experience of using therapy of inflammatory diseases of the women’s pelvic organs in reproductive age

The purpose of the study: to evaluate the effectiveness of the use of the drug bovgialuronidase azoximer in the complex therapy of inflammatory diseases of the pelvic organs in women of reproductive age. Material and methods. A comprehensive prospective clinical trial «Double-blind placebo-controlled multicenter randomized comparative study of the efficacy and safety of drugs, vaginal and rectal suppositories bovgialuronidase azoximer (NPO Petrovax Pharm LLC, Russia) in the complex therapy of patients with exacerbations of chronic inflammatory diseases of the pelvic organs» was conducted on the basis of the Clinic of FSBEI at KubSMU in 2017, which included 112 patients (average age 30.1±6.2 years). The patients were divided into 2 groups: group 1 - 58 women received the drug bovgialuronidase azoximer at a dose of 3000IU according to the scheme: 1 suppository rectally 1 time in 3 days 10 injections, then 1 suppository 1 time in 5 days 5 injections (total course - 15 suppositories); patients in the control group (n=54) received placebo suppositories, which were administered according to a similar scheme. Dynamic observation of the patients was carried out over the next three years. Results. In the patients of the main group, on the background of the treatment on day 5-7, subjective improvement was statistically significantly more frequent (50% vs 16.7%, respectively, x2=12.52, p=0.04). On the 10th-12th day, statistically significantly more often in the main group, positive dynamics of laboratory data (96.6% vs 68.5%, respectively, x2=15.5, p=0.04), normalization of vaginal biocenosis (96.6% vs 66.7%, respectively, x2=17.2, p=0.025) and subjective sensations (100% vs 87%, respectively,x2=7,906, p=0.04). With dynamic follow-up, the patients of the control group compared with the main group had a statistically significantly higher frequency of relapse of exacerbation of PID (31.5% vs 5.2%, x2=13.2, p=0.01) during the first 6 months of follow-up and during the first year of follow-up (40.7% vs 8.6%, x2=15.8, p=0.025), the onset of pregnancy is statistically significantly lower (25.9% vs 55.2%, x2=9.5, p= 0.04). Conclusion. The data revealed by us indicate that in women with PID who received, along with standard methods of treatment, the drug bovgialuronidase azoximer, there was a faster (3-5 days compared to the control group) disappearance of the main clinical symptoms, the number of pregnancies that occurred.